TGTX
Tg Therapeutics Inc
NASDAQ · Biotechnology
$28.86
+1.10 (+3.96%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 325.77M | 1.04B | 1.08B | 956.87M |
| Net Income | 23.15M | 129.57M | 136.18M | 105.42M |
| EPS | — | — | — | — |
| Profit Margin | 7.1% | 12.5% | 12.7% | 11.0% |
| Rev Growth | +266.4% | +16.6% | +24.3% | +11.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.20B | 908.15M | 880.79M | 975.86M |
| Total Equity | 1.09B | 2.79B | 2.78B | 2.56B |
| D/E Ratio | 1.10 | 0.33 | 0.32 | 0.38 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 49.20M | 169.61M | 170.48M | 149.89M |
| Free Cash Flow | — | 110.01M | 140.89M | 136.27M |